IL17A and Alzheimer disease: We found that HLJDT exerts anti-AD effects by reducing the levels of classical Th2 cytokines, including IL-3, IL-4, IL-5, and IL-13, as well as regulating cytokines secreted by emerging T-lymphocyte subsets, including IL17A.